CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: A meta-analysis

Pharmacogenetics and Genomics

Volumn 15, Issue 3, 2005, Pages 151-158

  Patsopoulos, Nikolaos A ^a,b   Ntzani, Evangelia E ^a   Zintzaras, Elias ^b   Ioannidis, John P A ^a,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2D6; Meta analysis; Schizophrenia; Tardive dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; CLOZAPINE; CYTOCHROME P450 2D6; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL;

ALLELE; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; DNA POLYMORPHISM; ENZYME METABOLISM; EXTRAPYRAMIDAL SYMPTOM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOTE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

EID: 17644423416     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200503000-00003     Document Type: Article

References (40)

1. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46:1396-1408.
2. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50:723-733.
3. Ntzani EE, Ioannidis JP. Pharmacogenetics and association studies in schizophrenia. Drug Dev Res 2003; 60:152-63.
4. Cichon S, Nothen MM, Rietschel M, Propping P. Pharmacogenetics of schizophrenia. Am J Med Genet 2000; 97:98-106.
5. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2D6 allele nomenclature. http://www.imm.ki.se/CYPalleles/cyp2d6.htm
6. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
7. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedeberg's Arch Pharmacol 2004; 369:23-37.
8. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, Eichelbaum M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11:573-585.
9. Andreassen OA, MacEwan T, Gulbrandsen A, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 1997; 131: 174-179.
10. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170:23-26.
11. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32:101-106.
12. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998; 32: 107-113.
13. Ohmori O, Kojima H, Shinkai T, Terao T, Suzuki T, Abe K. Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry Res 1999; 87:239-244.
14. Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 2000; 56:679-683.
15. Lam LC, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VK, Kwong SL, et al. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 2001; 34:238-241.
16. Ellingrod VL, Schultz SK, Arndl S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for Cytochrome P450 2D6. Pharmacotherapy 2002; 22:1416-1419.
17. Jaanson P, Marandi T, Kiivet RA, Vasar V, Vaan S, Svensson JO, Dahl ML. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology 2002; 162:67-73.
18. Nikoloff D, Shim JC, Fairchild M, Patten N, Fijal BA, Koch WH, et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2002; 2:400-407.
19. Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 2003; 13:163-168.
20. Lohmann PL, Bagli M, Krauss H, Muller DJ, Schulze TG, Fangerau H, et al. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry 2003; 36:73-78.
21. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:93-202.
22. Petitti DB. Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis, 2nd edn New York, NY: Oxford University Press; 1998.
23. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci USA 2001; 98:831-836.
24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
25. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-309.
26. Guy W. ECDEU Assessment Manual for Psycopharmacology. Publication ADM 534-537. US Department of Health, Education and Welfare, Washington, DC; 1976.
27. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psycopharmacology 1979; 64:171-179.
28. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486-487.
29. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337:867-372.
30. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28: 99-112.
31. Arthur H, Dahl ML, Siwers B, Sjöqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995; 15:211-216.
32. Spina E, Ancione M, DiRosa AE, Meduri M, Caputi AR Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 1992; 42:347-348.
33. Vandel P, Haffen E, Vandel S, Bonin B, Nezelof S, Sechter D, et al. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol 1999; 55:659-665.
34. de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998; 155:1278-1280.
35. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414-425.
36. 3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27:105-119.
37. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9:442-473.
38. Ioannidis JP. Genetic associations: false or true? Trends Mol Med 2003; 9:135-138.
39. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361:567-571.
40. Kroemer HK, Eichelbaum M. 'It's the genes, stupid'. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56:2285-2298.